Back to Search Start Over

Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence.

Authors :
Lee-Saxton YJ
Egan CE
Bratton BA
Thiesmeyer JW
Greenberg JA
Marshall TE
Tumati A
Romero-Arenas M
Beninato T
Zarnegar R
Scognamiglio T
Fahey TJ 3rd
Finnerty BM
Source :
The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Mar 30. Date of Electronic Publication: 2024 Mar 30.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Context: The significance of low mitotic activity in papillary thyroid cancer (PTC) is largely undefined.<br />Objective: We aimed to determine the behavioral landscape of PTC with low mitotic activity compared to that of no- and high-mitotic activity.<br />Methods: A single-institution consecutive series of PTC patients from 2018-2022 was reviewed. Mitotic activity was defined as no mitoses, low (1-2 mitoses/2 mm2) or high (≥3 mitoses/2 mm2) per the World Health Organization. The 2015 American Thyroid Association risk stratification was applied to the cohort, and clinicopathologic features were compared between groups. For patients with ≥6 months follow-up, Cox regression analyses for recurrence were performed.<br />Results: 640 PTCs were included - 515 (80.5%) no mitotic activity, 110 (17.2%) low mitotic activity, and 15 (2.3%) high mitotic activity. Overall, low mitotic activity exhibited rates of clinicopathologic features including vascular invasion, gross extrathyroidal extension, and lymph node metastases in between those of no- and high-mitotic activity. PTCs with low mitotic activity had higher rates of intermediate- and high-risk ATA risk stratification compared to those with no mitotic activity (p < 0.001). Low mitotic activity PTCs also had higher recurrence rates (15.5% vs. 4.5%, p < 0.001). Low mitotic activity was associated with recurrence, independent of the ATA risk stratification (HR 2.96; 95% CI 1.28-6.87, p = 0.01).<br />Conclusions: Low mitotic activity is relatively common in PTC and its behavior lies within a spectrum between no- and high-mitotic activity. Given its association with aggressive clinicopathologic features and recurrence, low mitotic activity should be considered when risk stratifying PTC patients for recurrence.<br /> (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)

Details

Language :
English
ISSN :
1945-7197
Database :
MEDLINE
Journal :
The Journal of clinical endocrinology and metabolism
Publication Type :
Academic Journal
Accession number :
38554391
Full Text :
https://doi.org/10.1210/clinem/dgae203